Literature DB >> 34143403

Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Marios Adramerinas1, Dimitrios Andreadis2, Konstantinos Vahtsevanos3, Athanasios Poulopoulos4, Kalliopi Pazaitou-Panayiotou5.   

Abstract

PURPOSE: This study aims to elaborate on the current knowledge concerning the mechanism, frequency, clinical manifestations, diagnostic procedures, prevention, and management of radioactive iodine (RAI)-induced sialadenitis in patients receiving treatment for differentiated thyroid cancer (DTC).
METHODS: A review of the literature was carried out through the " www.ncbi.nlm.nih.gov/pubmed " database focusing on the results of the past decade.
RESULTS: The high concentration of RAI in the salivary glands results in high beta radiation exposure of the striated duct cells and stem cells. This exposure leads to acute and/or chronic sialadenitis with obstructive symptoms and progressive loss of salivary gland function and xerostomia, with severe impact on patients' quality of life. No standard diagnostic method has been established. As far as prevention is concerned, many approaches have been proposed, such as sialogogues, local massage, vitamin E, and amifostine administration. Although there is no unanimity as to their effectiveness, the use of sialogogues is recommended. Treatment includes conservative drug therapy and sialendoscopy when necessary.
CONCLUSION: RAI-induced sialadenitis has a major impact on patients' quality of life. Due to the good prognosis of DTC, the reduction of sialadenitis and its prognosis, prevention, and treatment constitute a priority for the overall treatment of these patients. Further studies that will establish a coherent treatment protocol for this condition are necessary.
© 2021. Hellenic Endocrine Society.

Entities:  

Keywords:  Differentiated thyroid cancer; Radioactive iodine therapy; Sialadenitis; Xerostomia

Mesh:

Substances:

Year:  2021        PMID: 34143403     DOI: 10.1007/s42000-021-00304-3

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  61 in total

1.  Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands.

Authors:  C Spitzweg; W Joba; K Schriever; J R Goellner; J C Morris; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

2.  Emptying effect of massage on parotid gland radioiodine content.

Authors:  Chae Moon Hong; Seung Hyun Son; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Commun       Date:  2014-11       Impact factor: 1.690

3.  Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study.

Authors:  Fabricio Lopes da Fonseca; Patricia Kazue Yamanaka; Luciana Mazoti; Lica Arakawa-Sugueno; Juliana Mika Kato; Suzana Matayoshi
Journal:  Head Neck       Date:  2017-09-25       Impact factor: 3.147

Review 4.  Anatomy, biogenesis and regeneration of salivary glands.

Authors:  Kyle V Holmberg; Matthew P Hoffman
Journal:  Monogr Oral Sci       Date:  2014-05-23

5.  Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine.

Authors:  Edward B Silberstein
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

6.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

7.  Modulation of sodium/iodide symporter expression in the salivary gland.

Authors:  Krista M D La Perle; Dong Chul Kim; Nathan C Hall; Adam Bobbey; Daniel H Shen; Rebecca S Nagy; Paul E Wakely; Amy Lehman; David Jarjoura; Sissy M Jhiang
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

8.  Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis.

Authors:  Young-Mo Kim; Jeong-Seok Choi; Seong Bin Hong; In Young Hyun; Jae-Yol Lim
Journal:  Head Neck       Date:  2015-01-27       Impact factor: 3.147

9.  The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure.

Authors:  Ayşe Aktaş; Kevser Kavak; Beyza Kocabaş; Murat Aras; Neslihan Başcl Tütüncü; Arzu Gençoğlu
Journal:  Nucl Med Commun       Date:  2008-11       Impact factor: 1.690

Review 10.  Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer.

Authors:  D Van Nostrand
Journal:  Oral Dis       Date:  2010-10-28       Impact factor: 3.511

View more
  1 in total

1.  Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching.

Authors:  Ye Liu; Yuhua Wang; Wanchun Zhang
Journal:  Front Surg       Date:  2022-09-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.